AI Article Synopsis
- Granulomatosis with polyangiitis (GPA) is a serious autoimmune condition affecting blood vessels, leading to symptoms like fatigue and severe complications like lung issues and kidney damage.
- A case study highlights a 66-year-old man with GPA who experienced severe symptoms, including lung bleeding and kidney failure, requiring aggressive treatment with various medications.
- Early diagnosis and treatment are crucial for protecting organ function in patients with GPA, but more research is needed to find the most effective treatment combinations.
Article Abstract
Granulomatosis with polyangiitis (GPA) is a systemic vasculitis that affects blood vessels and presents with vague constitutional symptoms, but more serious manifestations can develop, including pulmonary complications and glomerulonephritis. Currently, there are no definitive treatment guidelines. We present a case of a 66-year-old male with no previous medical history who was admitted for generalized constitutional symptoms for the past month. Imaging of the patient's brain revealed dural enhancement. Bronchoalveolar lavage was done and revealed diffuse alveolar hemorrhage (DAH). A kidney biopsy revealed granulomatosis with polyangiitis. The patient's hospital course was complicated by acute renal failure and required hemodialysis. Due to the patient's multi-organ involvement, the patient was treated aggressively with cyclophosphamide, rituximab, plasma exchange (PE), and steroids. GPA is a systemic vasculitis that can present with multi-organ involvement. A prompt diagnosis is necessary to initiate treatment and preserve organ function. More research is needed to determine which combination therapies are the best treatment modalities in cases of severe multi-organ system involvement.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329316 | PMC |
| http://dx.doi.org/10.7759/cureus.64765 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Unique Case Linking Rituximab to a Ureaplasma Infection and Life-Threatening Hyperammonemia.
Cureus
November 2024
Pulmonary & Critical Care, Indiana University Health Methodist Hospital, Indianapolis, USA.
Rituximab is an anti-CD20 monoclonal antibody medication used in treating various cancers like non-Hodgkin lymphomas as well as immunologic conditions like granulomatosis with polyangiitis. It disrupts and decreases the number of B-cells, which causes an immunosuppressive state. This can promote the growth of numerous rare and opportunistic pathogens, one of which is .
View Article and Find Full Text PDFRemission induction therapies and long-term outcomes in granulomatosis with polyangiitis and microscopic polyangiitis: real-world data from a European cohort.
Rheumatol Int
December 2024
Department of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany.
To explore disease characteristics, renal involvement and induction treatment strategies over the last decades and evaluate relapse rates and renal outcomes in ANCA-associated vasculitides (AAV). We retrospectively analyzed remission, relapse rates and the occurrence of the composite endpoint (comprising death and renal failure) in newly diagnosed AAV cases in four tertial referral centers in Germany and Switzerland diagnosed between 1999 and 2022. Hazard ratios were computed by Cox proportional hazard and Kaplan-Meier curves were plotted to compare therapeutic strategies after propensity-matching.
View Article and Find Full Text PDFGlucocorticoid tapering pace in microscopic polyangiitis and granulomatosis with polyangiitis in Japanese real-world practice: A propensity score-matched retrospective cohort study from the J-CANVAS registry.
Mod Rheumatol
December 2024
Department of Nephrology and Rheumatology, Graduate School of Medical Science, Kanazawa University.
Objective: To assess the prevalence and outcomes among regimens of glucocorticoid tapering for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) in real-world practice.
Methods: We retrospectively examined the Japan Collaborative Registry of ANCA-associated Vasculitis (J-CANVAS) registry, and evaluated the prevalence of glucocorticoid tapering regimens in the PEXIVAS trial. In patients with newly diagnosed MPA and GPA, we compared outcomes among standard and reduced pace regimens.
Pediatric eosinophilic granulomatosis with polyangiitis and intracardiac thrombus: A case report.
SAGE Open Med Case Rep
December 2024
Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic necrotizing vasculitis marked by eosinophilia and extravascular granulomas, predominantly affecting the respiratory tract. This report details a unique EGPA case in a 6-year-old girl with extensive cardiac involvement, featuring an atypical intracardiac mass suggestive of endomyocardial fibrosis and a concomitant thrombus. The clinical course unfolded in three phases: an initial prodrome with asthma; subsequent peripheral hypereosinophilia; and ultimately systemic vasculitis.
View Article and Find Full Text PDFReduction of Chronic Fatigue Through Transcranial Direct Current Stimulation and Low-Intensity Aerobic Exercise: A Case Study of Two Patients With Granulomatosis With Polyangiitis.
Cureus
November 2024
Rheumatology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, BRA.
Granulomatosis with polyangiitis (GPA) is a systemic vasculitis that can lead to persistent pain and fatigue, significantly impacting patients' quality of life. This study assessed the effects of transcranial direct current stimulation (tDCS) combined with aerobic exercise as a non-pharmacological intervention for managing fatigue in GPA patients. Two patients were randomly assigned to receive either active tDCS or simulated tDCS stimulation (sham) during low-intensity aerobic exercise.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!